Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 577

1.
2.

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.

Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegård M, Reist C, Patel MR; EUCLID Trial Steering Committee and Investigators..

N Engl J Med. 2017 Jan 5;376(1):32-40. doi: 10.1056/NEJMoa1611688. Epub 2016 Nov 13.

PMID:
27959717
3.

Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies.

Barbieri L, Verdoia M, Schaffer A, Suryapranata H, De Luca G.

Cardiovasc Drugs Ther. 2016 Dec;30(6):611-622.

PMID:
27757726
4.

Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.

Rosa GM, Bianco D, Valbusa A, Massobrio L, Chiarella F, Brunelli C.

Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1491-1502. Epub 2016 Oct 24. Review.

PMID:
27715344
5.

Dual antiplatelet therapy for secondary stroke prevention: Use of clopidogrel and acetylsalicylic acid after noncardioembolic ischemic stroke.

Koziol K, Van der Merwe V, Yakiwchuk E, Kosar L.

Can Fam Physician. 2016 Aug;62(8):640-5. Review. No abstract available.

6.

Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.

Jackson LR 2nd, Piccini JP, Cyr DD, Roe MT, Neely ML, Martinez F, Lüscher TF, Lopes RD, Winters KJ, White HD, Armstrong PW, Fox KA, Prabhakaran D, Bhatt DL, Magnus Ohman E, Corbalán R.

Clin Cardiol. 2016 Sep;39(9):497-506. doi: 10.1002/clc.22562. Epub 2016 Jul 28.

7.

Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis.

Zhao Z, Li X, Sun S, Mei S, Ma N, Miao Z, Zhao M, Peng S.

Eur J Clin Pharmacol. 2016 Oct;72(10):1195-204. doi: 10.1007/s00228-016-2094-1. Epub 2016 Jul 23.

PMID:
27450232
8.

Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.

Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, Wang Y; CHANCE investigators..

JAMA. 2016 Jul 5;316(1):70-8. doi: 10.1001/jama.2016.8662.

PMID:
27348249
9.
10.

Effects of Sarpogrelate Combined with Aspirin in Patients Undergoing Carotid Endarterectomy in China: A Single-Center Retrospective Study.

Guo J, Gu Y, Guo L, Yu H, Qi L, Tong Z, Zhang J, Wang Z.

Ann Vasc Surg. 2016 Aug;35:183-8. doi: 10.1016/j.avsg.2016.01.032. Epub 2016 May 27.

PMID:
27238992
11.

Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.

Hagström E, Roe MT, Hafley G, Neely ML, Sidhu MS, Winters KJ, Prabhakaran D, White HD, Armstrong PW, Fox KA, Ohman EM, Boden WE; TRILOGY ACS Investigators..

Clin Cardiol. 2016 Jun;39(6):329-37. doi: 10.1002/clc.22533. Epub 2016 May 13.

12.

Extended use of clopidogrel and aspirin after ischemic stroke.

Davis K, Dietrich E.

Am J Health Syst Pharm. 2016 May 15;73(10):611-2. doi: 10.2146/ajhp150993. No abstract available.

PMID:
27147209
13.

Extended use of clopidogrel and aspirin after ischemic stroke.

Shiue HJ, Sands KA.

Am J Health Syst Pharm. 2016 May 15;73(10):611. doi: 10.2146/ajhp150859. No abstract available.

PMID:
27147208
14.

Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.

Li Z, Wang Y, Zhao X, Liu L, Wang D, Wang C, Meng X, Li H, Pan Y, Wang X, Wang C, Yang X, Zhang C, Jing J, Xian Y, Johnston SC, Wang Y; CHANCE Investigators..

J Am Heart Assoc. 2016 Mar 21;5(3):e003038. doi: 10.1161/JAHA.115.003038.

15.

A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.

Povsic TJ, Roe MT, Ohman EM, Steg PG, James S, Plotnikov A, Mundl H, Welsh R, Bode C, Gibson CM.

Am Heart J. 2016 Apr;174:120-8. doi: 10.1016/j.ahj.2016.01.004. Epub 2016 Jan 18.

16.

Effects of Arnica comp.-Heel® on reducing cardiovascular events in patients with stable coronary disease.

Fioranelli M, Bianchi M, Roccia MG, Di Nardo V.

Minerva Cardioangiol. 2016 Feb;64(1):34-40.

PMID:
26989948
17.

Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.

Niu PP, Guo ZN, Jin H, Xing YQ, Yang Y.

BMJ Open. 2016 Mar 17;6(3):e009013. doi: 10.1136/bmjopen-2015-009013. Review.

18.

Impact of preoperative dual antiplatelet therapy on bleeding complications in patients with acute coronary syndromes who undergo urgent coronary artery bypass grafting.

Nagashima Z, Tsukahara K, Uchida K, Hibi K, Karube N, Ebina T, Imoto K, Kimura K, Umemura S.

J Cardiol. 2017 Jan;69(1):156-161. doi: 10.1016/j.jjcc.2016.02.013. Epub 2016 Mar 15.

PMID:
26987791
19.

Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.

Noh Y, Lee J, Shin S, Lim HS, Bae SK, Oh E, Kim GJ, Kim JH, Lee S.

PLoS One. 2016 Mar 3;11(3):e0150475. doi: 10.1371/journal.pone.0150475. eCollection 2016 Mar 3.

20.

Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation.

Nijenhuis VJ, Bennaghmouch N, Hassell M, Baan J Jr, van Kuijk JP, Agostoni P, van 't Hof A, Kievit PC, Veenstra L, van der Harst P, van den Heuvel AF, den Heijer P, Kelder JC, Deneer VH, van der Kley F, Onorati F, Collet JP, Maisano F, Latib A, Huber K, Stella PR, Ten Berg JM.

Am Heart J. 2016 Mar;173:77-85. doi: 10.1016/j.ahj.2015.11.008. Epub 2015 Dec 1.

PMID:
26920599

Supplemental Content

Loading ...
Support Center